Overview

* Delcath ( DCTH ) Q3 revenue of $20.6 mln missed analyst expectations

* Net income for Q3 was $0.8 mln, down from $1.9 mln last year

* Company achieved positive adjusted EBITDA of $5.3 mln in Q3

Outlook

* Delcath ( DCTH ) expects 2025 revenue between $83 mln and $85 mln

* Company anticipates gross margins of 85% to 87% in 2025

* Delcath ( DCTH ) projects positive adjusted EBITDA and cash flow each quarter of 2025

Result Drivers

* HEPZATO KIT SALES - Revenue from HEPZATO KIT increased significantly to $19.3 mln from $10.0 mln in Q3 2024, driving overall revenue growth

* R&D costs rise - R&D expenses were $8.0 million compared to $3.9 million last year

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $20.56 $23.80

Revenue mln mln (7

Analysts

)

Q3 EPS $0.02

Q3 Net $830,000

Income

Q3 Gross $17.93

Profit mln

Q3 $18.32

Operatin mln

g

Expenses

Q3 -$388,00

Operatin 0

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Delcath Systems Inc ( DCTH ) is $23.00, about 58.6% above its November 3 closing price of $9.52

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)